UBE (4208) FY2026 Q3 Earnings Report

Quick View

Executive Summary

For the cumulative Q3 period of the fiscal year ending March 2026, UBE improved its operating margin despite a decline in revenue and the acquisition of the Urethane Systems business through a major M&A transaction. Revenue was ¥332.15B (-7.6% YoY, -¥27.47B), Operating Income was ¥14.50B (+52.0% YoY, +¥4.96B), Ordinary Income was ¥30.35B (+133.9% YoY, +¥17.37B), and Net Income attributable to owners of the parent was ¥21.11B, representing a turnaround from the ¥24.71B net loss recorded in the same period of the previous year. The main reasons for the revenue decline were the contraction of the Machinery Business, which was excluded from the segment following the transfer of management control of the Steelmaking Business in the previous year, and lower selling prices for resins and chemicals. The primary drivers of profit growth were the turnaround to profitability in the Resins & Chemicals segment and the ¥12.76B increase in equity-method investment gain and ¥3.94B foreign exchange gain at the Ordinary Income level.

Factors Affecting Business Results

【Revenue】Revenue was ¥332.15B, down 7.6% YoY. The Machinery Business recorded a 25.1% revenue decline due to its exclusion from consolidation following the transfer of management control of the Steelmaking Business in the previous year, while Pharmaceuticals declined 42.3% due to lower contract-manufacturing volumes. In contrast, Advanced Urethane expanded rapidly, with revenue increasing 175.7% due to the acquisition of the Urethane Systems business, partially offsetting the overall decline.

【Profit and Loss】Operating Income was ¥14.50B (+52.0% YoY), with the positive price variance of ¥6.0B and fixed-cost efficiency gains of ¥2.3B exceeding the negative volume variance of ¥3.3B. Resins & Chemicals turned profitable, improving from a loss of ¥2.4B in the previous year to profit of ¥8.1B, primarily due to lower depreciation and amortization expenses following impairment losses in the previous period and lower repair expenses as the ammonia plant was not in a scheduled major-repair year. This was the main driver of profit growth. Ordinary Income was ¥30.35B, ¥15.85B higher than Operating Income, with non-operating factors including ¥12.76B in equity-method investment gain and ¥3.94B in foreign exchange gain making significant contributions. Extraordinary losses totaled ¥2.52B, including impairment losses of ¥1.57B, a substantial decrease from the ¥37.72B in extraordinary losses recorded in the previous year, which included ¥30.28B in impairment losses. The reduction in one-time losses also contributed to the turnaround to net profitability. In conclusion, the Company achieved higher profit despite lower revenue.

Segment Analysis

Resins & Chemicals had the largest revenue mix, accounting for 55.6%, and is positioned as the core business. Its Operating Income was ¥8.10B, representing a turnaround from the ¥-2.40B recorded in the previous year and making it the largest contributor to company-wide profit growth. Specialty Products maintained the highest operating margin among all segments, with Operating Income of ¥6.69B and a margin of 14.9%. Meanwhile, Advanced Urethane expanded rapidly to revenue of ¥31.51B, but recorded an operating loss of ¥-1.40B due to PMI (integration) costs. Pharmaceuticals also recorded a loss of ¥-0.89B. Machinery declined year on year in both revenue and profit, with Operating Income of ¥3.86B, down 21.4%, although its 8.3% margin remained relatively stable. There are significant disparities in profitability among the segments, and the recovery of Resins & Chemicals and the monetization of the Urethane business will determine the Company’s overall profit margin going forward.

Key Financial Indicators

Profitability: ROE was 6.5% (annualized), while the Operating Income margin was 4.4%, improving from 2.7% in the previous year.
Cash flow quality: Operating Cash Flow (OCF) / Net Income was 1.54x, while FCF was ¥-85.01B, as Investing Cash Flow of ¥-117.48B exceeded OCF of ¥32.47B.
Investment efficiency: Capital expenditures (acquisition of PPE and intangible assets) were ¥51.13B versus depreciation and amortization of ¥18.96B, resulting in capital expenditures / depreciation and amortization of 2.7x and indicating a growth-investment phase.
Financial soundness: The Equity Ratio was 47.7%, up from 45.6% in the previous year, and the current ratio was 164.0%.

Cash Flow Analysis

OCF was ¥32.47B, or 1.54x Net Income of ¥21.11B, indicating sound cash backing for earnings. Investing Cash Flow was ¥-117.48B, mainly due to ¥71.53B for the acquisition of shares in subsidiaries and ¥51.13B for the acquisition of PPE and intangible assets. Financing Cash Flow was an inflow of ¥15.79B, with the net increase in long-term borrowings and other items financing part of the investments. FCF was ¥-85.01B, and cash and cash equivalents declined substantially year on year. Cash-generation quality requires monitoring, and the transition to a cash-recovery phase following the major investments will be a key focus going forward.

Quality of Earnings

Ordinary Income of ¥30.35B exceeded Operating Income of ¥14.50B by ¥15.85B, representing a large gap of approximately 109%. The primary reasons were non-operating income from equity-method investment gain of ¥12.76B and foreign exchange gain of ¥3.94B, which accounted for the majority of total non-operating income of ¥20.19B. Non-operating income was equivalent to 6.1% of revenue, exceeding the 5% benchmark. Net extraordinary income and losses amounted to ¥-2.19B, including impairment losses of ¥1.57B, a decrease from the large impairment loss of ¥30.28B in the previous year. The reduction in one-time losses also contributed to the recovery in Net Income. OCF exceeded Net Income, indicating limited concern regarding accrual quality; however, attention is required because the increase in Ordinary Income and Net Income included highly non-recurring factors such as equity-method income and foreign exchange gains.

Earnings Forecast and Guidance

The Q3 cumulative progress rates against the full-year forecasts of Revenue of ¥490.00B, Operating Income of ¥25.00B, and Ordinary Income of ¥37.50B were 67.8%, 58.0%, and 80.9%, respectively. Compared with the standard progress rate of 75%, Operating Income was 17.0pt below the benchmark, requiring standalone Q4 Operating Income of ¥10.00B, equivalent to 40.0% of the full-year forecast. Ordinary Income, by contrast, was progressing above the standard rate, with the difference in progress rates reflecting the Company’s reliance on non-operating factors such as equity-method investment gain and foreign exchange gain.

Shareholder Returns

The annual dividend forecast is ¥110.00 per share, comprising an interim dividend of ¥55.00 and a year-end dividend of ¥55.00. Based on the full-year Net Income forecast of ¥27.50B and forecast EPS of ¥283.15, the Payout Ratio is approximately 38.8%. Share repurchases were minimal at ¥0.004B, and the Total Return Ratio is therefore broadly in line with the Payout Ratio. OCF of ¥32.47B covers the estimated total annual dividend of approximately ¥10.67B, based on the number of shares outstanding, by approximately 3.0x, ensuring the Company’s cash capacity to pay dividends. However, FCF is negative, and the Company is not in a position to fund both dividends and major investments solely through internally generated funds.

Catalysts

【Short Term】The sustainability of profitability improvements in Resins & Chemicals during Q4 and the extent to which progress toward achieving the full-year Operating Income plan can be recovered.

【Long Term】Progress in PMI and the monetization of the Urethane Systems business, as well as the acceleration of structural reforms for ammonia, caprolactam, and nylon polymer from March 2026 to March 2028.

Industry Benchmark (Reference; Compiled by the Company)

Industry Benchmark (manufacturing)

Profitability and Returns

The Operating Income margin is 4.2pt below the industry median, while the Net Income margin is slightly above the median due to the contribution of non-operating income.

Growth and Capital Efficiency

The Revenue growth rate is substantially below the industry median, indicating that the Company is in a period of declining revenue associated with structural reforms and business restructuring.

※Source: Compiled by the Company

Risk Factors

1. High leverage: Long-term borrowings increased 19.3% YoY to ¥185.70B due to major investments, including ¥71.53B for the acquisition of shares in subsidiaries. The impact of higher interest-bearing debt on financial costs requires continuous monitoring.

2. Increase in goodwill and intangible assets: Following the acquisition of the Urethane Systems business, goodwill increased sharply to ¥42.21B and intangible fixed assets to ¥56.99B. If the acquired business fails to meet its earnings plan, this could lead to future impairment risk.

3. Reliance on non-operating income: Equity-method investment gain of ¥12.76B and foreign exchange gain of ¥3.94B, which supported Ordinary Income, are highly non-recurring items that may fluctuate depending on the performance of affiliated companies and foreign exchange movements.

Key Points in the Earnings Results

1. The Resins & Chemicals segment turned profitable due to lower depreciation and amortization expenses following impairment losses in the previous period and lower repair expenses. However, these factors include temporary elements, and their sustainability from the next fiscal year onward may be limited.

2. While the full-year progress rate for Operating Income was 58.0%, below the standard rate, Ordinary Income and Net Income showed strong progress due to non-operating factors. The extent of the recovery in core-business profitability is therefore difficult to assess based solely on Ordinary Income.

3. Despite rapid revenue growth, the Advanced Urethane segment remained loss-making due to PMI costs. The elimination of integration costs and progress toward monetization will be key points of focus going forward.

Theoretical Share Price (Reference Value)

Sensitivity: ¥4,173–¥4,416 at Cost of Equity ±1%, and ¥4,282–¥4,298 at ω±0.1.

Notes:

• Goodwill amortization of ¥20.9 per share is added back to earnings for comparability with companies that do not incur this non-cash expense and with IFRS companies.
• Because forecast ROE is below the Cost of Equity, the theoretical value is below Book Value per Share.
• Net assets as of the quarter-end are used, resulting in a timing difference from the full-year forecast.
• Because net assets include non-controlling interests, the theoretical value may be calculated at a somewhat higher level.

(Calculation model: Residual Income Model (Ohlson type; explicit 5-year fade) / Interest-rate reference month: 2026-07 / Mechanically calculated value based solely on publicly disclosed data; it is not a forecast of the market share price or a recommendation of any specific investment action, and does not predict or guarantee the future share price.)

---

This report is an earnings analysis document automatically generated by AI through integrated analysis of XBRL earnings summary data and PDF earnings presentation materials. It does not recommend investment in any specific security. The industry benchmarks are reference information compiled by the Company based on publicly disclosed earnings data. Investment decisions should be made at your own responsibility, after consulting a professional as necessary.